Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer.

Trial Profile

Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Nov 2014

At a glance

  • Drugs Trastuzumab (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Paclitaxel
  • Indications Breast cancer; Early breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Aug 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
    • 11 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Feb 2011 Planned end date changed from 1 Apr 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top